Analyst Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics and keeping the price target at $10.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anthony Vendetti has given his Buy rating due to a combination of factors that highlight Dermata Therapeutics’ strategic direction and financial outlook. The company is progressing with its plan to launch an over-the-counter acne treatment kit in mid-2026, leveraging its proprietary Spongilla technology. This strategic shift towards the FDA OTC monograph pathway is seen as a prudent move, as it reduces the time to market and regulatory hurdles, while also lowering capital requirements.
Dermata’s financial position appears stable, with $4.7 million in cash and no debt, which is expected to sustain operations into the second quarter of 2026. Although the company is currently pre-revenue, the anticipated launch of its product and the potential expansion into broader e-commerce and retail channels in 2027 support a positive long-term outlook. Despite the uncertainties associated with the early stages of this strategic pivot, the valuation remains compelling, and the company is expected to conduct trials to bolster its marketing efforts. As a result, Vendetti maintains a Buy rating, reflecting confidence in Dermata’s future prospects.